Chemotherapy-induced myelosuppression, which includes neutropenia, anemia, and thrombocytopenia, significantly impacts patients' quality of life (QoL). These conditions result from chemotherapy's damage to hematopoietic stem and progenitor cells in the bone marrow, leading to reduced production of blood cells. Symptoms such as fatigue, infection risk, and bleeding can severely affect daily activities and emotional well-being. Traditional treatments like granulocyte colony-stimulating factors (G-CSF), erythropoiesis-stimulating agents (ESAs), and blood transfusions are used to manage myelosuppression but often come with side effects that further reduce QoL. Trilaciclib, approved by the FDA for use in patients with extensive-stage small-cell lung cancer, has shown promise in reducing myelosuppression and its symptoms. It works by temporarily halting the division of hematopoietic stem and progenitor cells, protecting them from chemotherapy damage. Clinical trials have demonstrated that trilaciclib reduces the duration and occurrence of severe neutropenia, anemia, and thrombocytopenia, leading to improved QoL. Other investigational agents, such as plinabulin and roxadustat, are also being developed to manage myelosuppression and may offer additional benefits. Chemotherapy-induced myelosuppression is often managed with dose reductions or delays, which can negatively affect treatment outcomes. Supportive care interventions, including G-CSF, ESAs, and transfusions, are associated with risks and limitations that can further burden patients. However, trilaciclib and other emerging treatments offer a proactive approach to reducing myelosuppression and its symptoms, potentially improving QoL for patients undergoing chemotherapy. Future research and development of these agents may expand treatment options and enhance supportive care for patients with cancer.Chemotherapy-induced myelosuppression, which includes neutropenia, anemia, and thrombocytopenia, significantly impacts patients' quality of life (QoL). These conditions result from chemotherapy's damage to hematopoietic stem and progenitor cells in the bone marrow, leading to reduced production of blood cells. Symptoms such as fatigue, infection risk, and bleeding can severely affect daily activities and emotional well-being. Traditional treatments like granulocyte colony-stimulating factors (G-CSF), erythropoiesis-stimulating agents (ESAs), and blood transfusions are used to manage myelosuppression but often come with side effects that further reduce QoL. Trilaciclib, approved by the FDA for use in patients with extensive-stage small-cell lung cancer, has shown promise in reducing myelosuppression and its symptoms. It works by temporarily halting the division of hematopoietic stem and progenitor cells, protecting them from chemotherapy damage. Clinical trials have demonstrated that trilaciclib reduces the duration and occurrence of severe neutropenia, anemia, and thrombocytopenia, leading to improved QoL. Other investigational agents, such as plinabulin and roxadustat, are also being developed to manage myelosuppression and may offer additional benefits. Chemotherapy-induced myelosuppression is often managed with dose reductions or delays, which can negatively affect treatment outcomes. Supportive care interventions, including G-CSF, ESAs, and transfusions, are associated with risks and limitations that can further burden patients. However, trilaciclib and other emerging treatments offer a proactive approach to reducing myelosuppression and its symptoms, potentially improving QoL for patients undergoing chemotherapy. Future research and development of these agents may expand treatment options and enhance supportive care for patients with cancer.